阿立哌唑与泰必利治疗儿童抽动障碍的对照研究

A control study of aripiprazole and tiapride treatment for tic disorders in children

摘要:

目的：比较阿立哌唑与泰必利治疗儿童抽动障碍的疗效和安全性。方法：将65例6～14岁抽动障碍患儿随机分为两组，分别给予阿立哌唑(2.5~10 mg/d)与泰必利(25~400 mg/d)治疗，观察疗程12周后用《耶鲁综合抽动严重程度量表(YGTSS)评分表》评定临床疗效并观察不良反应。结果：从治疗第2周末起阿立哌唑组和泰必利组YGTSS总分得分均下降，但在第2周时阿立哌唑组下降率为（29±13）%，明显高于泰必利组下降率［（16±14）%,P<0.01］。治疗12周后，阿立哌唑组和泰必利组治疗总体有效率分别为91%和84%，差异无统计学意义。阿立哌唑组和泰必利组不良反应的发生率差异无统计学意义，且两组均未见严重不良反应。结论：小剂量阿立哌唑治疗儿童抽动障碍起效快、疗效好、有较好的安全性，为临床治疗儿童抽动障碍提供了一种新的药物选择。［中国当代儿科杂志，2010，12（6）：421-424］

Abstract:

OBJECTIVE: To evaluate the efficacy and safety of aripiprazole in the treatment of tic disorder when tiapride is used as a control. METHODS: Sixty-five children aged 6-14 years old with tic disorders were randomly assigned to two groups: aripiprazole (2.5-10 mg/d) and tiapride treatment (25- 400 mg/d). After 12 weeks treatment, the clinical efficacy was assessed by the Yale Global Tie Severity Scale (YGTSS) score and the adverse reactions were observed. RESULTS: The YGTSS score in both groups decreased from the second week of treatment. Compared with the tiapride treatment group, the aripirazole treatment group showed a more decreased YGTSS score ［(29±13)% vs (16±14)%; P<0.01］ by the second week of treatment. The overall effective rate in the aripiprazole and tiapride treatment groups was 91% and 84%, respectively (P>0.05) 12 weeks after treatment. There were no significant differences in the incidence of adverse reactions between the aripiprazole and tiapride treatment groups and no severe adverse events were found in either group. CONCLUSIONS: Low dose aripiprazole is safe and effective for treatment of tic disorders in children, suggesting that it represents a new valid option for the treatment of tic disorder.［Chin J Contemp Pediatr, 2010, 12 (6):421-424］